A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials
采用多层方法开发经过验证的检测方法,以预测四价登革热病毒减毒活疫苗在 II 期和 III 期临床试验中的功效
基本信息
- 批准号:9153368
- 负责人:
- 金额:$ 126.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-13 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdvocateAntibodiesArthropodsAttenuatedBiological AssayBrazilCellsCellular AssayClinicalClinical DataClinical ResearchClinical TrialsCommunicable DiseasesCountryDataData AnalysesDecision MakingDengue InfectionDengue VirusDevelopmentDiseaseDoseEconomic BurdenEffector CellEpidemicEquilibriumFar EastFlavivirusGenesGuidelinesHumanHumoral ImmunitiesImmuneImmune responseIncidenceIndividualInfectionInfectious AgentLifeMeasuresMediatingNatural ImmunityPeripheral Blood Mononuclear CellPhasePhase III Clinical TrialsPlacebosPlasmaPredictive ValueRecruitment ActivityReportingRunningSamplingScheduleSerologicalSerotypingSouth AmericaSoutheastern AsiaStatistical Data InterpretationStructural GenesT-LymphocyteTestingTrainingTreesVaccinatedVaccinesValidationViralVirusVirus DiseasesWorkYellow fever virusadaptive immunityassay developmentburden of illnesscase controlcohortexperiencegenome-widehigh throughput screeningimmunogenicityin vitro Assaymembernovelphase 1 studyphase III trialpredict clinical outcomeprogramsseropositivevaccine developmentvaccine efficacyvaccine responsevaccine trialvaccine-induced immunityvirology
项目摘要
Dengue virus (DENV) infection has reached epidemic proportions in many countries in South America and
Southeast Asia, with most experts advocating for a safe and efficacious vaccine to stop dissemination and
reduce viral economic and disease burden. Advanced clinical trials of the Sanofi-Pasteur chimeric DENV-
yellow fever virus (YFV) vaccine reported only partial protection and did not show efficacy against all DENV
serotypes or in DENV-naive subjects. Most concerning, recent data has indicated that the Sanofi vaccine might
enhance symptomatic disease in naive subjects, which has raised questions as to its eventual deployment.
The lack of established immune correlates of vaccine-induced protection has hampered the development of a
safe efficacious vaccine to DENV and to several other infectious diseases. Recent conceptual and
technological advances in our understanding of effector mechanisms of cell and humoral immunity pave the
way forward for implementing new assays that identify mechanisms and correlates of vaccine efficacy. A new
live-attenuated DENV vaccine currently is being tested in Brazil, one of the countries where DENV has
reached epidemic proportions. This TV003 vaccine formulation includes three attenuated strains corresponding
to different DENV serotypes (DENV-1, DENV-3, and DENV-4) and a fourth chimeric strain (DENV-2/DENV-4),
which contains the DENV-2 structural genes and the DENV-4 non-structural genes. One of the major
advantages of the TV003 vaccine relative to the Sanofi DENV-YFV vaccine is that all of its components are
from DENV strains. A Phase II trial of this vaccine has been completed and a Phase III trial has been initiated
and will include over 17,000 subjects. Both phase II and III trials have been powered to include enough
subjects to have training and test/validation cohorts. Peripheral blood mononuclear cells, serum and plasma
have been collected on all subjects included in these two landmark studies. The major objective of our study
will be to compare, prioritize and select the best assay that predicts the immunogenicity and the efficacy of this
vaccine. We will test the hypothesis that several components (cellular, humoral and innate) are required
to trigger the protection induced by this vaccine. The assays that will be tested here encompass a wide
array of effector mechanisms of the cellular and humoral immune responses as well as novel genome-wide
unbiased assessment of innate and adaptive immunity. A rigorous decision making tree will allow us in Aim 1
to identify and validate assays that predict a vaccine triggered broad immune response that targets all four
DENV strains included in this vaccine. In Aim 2 we will identify the best in class assay(s) that predicts the
efficacy of the vaccine in protecting recipients from infection. Efficacy will involve comparison of cases and
controls if the vaccine's efficacy is below 80%; alternatively we will compare vaccinees and naturally infected
placebos if the vaccine is highly efficacious (>85%). In Aim 3 our corporate partner Caprion, who has long
standing experience in developing predictors of clinical outcome, will further optimize and scale the assay(s)
identified in Aim 1 (immunogenicity) and in Aim 2 (efficacy) for robustness, accuracy, and throughput required
for widespread clinical use in vaccine trials of DENV, and possibly other viruses.
登革热病毒(DENV)感染已在南美洲和许多国家达到流行程度
东南亚,大多数专家倡导安全有效的疫苗,以阻止传播和
减少病毒式经济和疾病负担。赛诺菲-巴斯德嵌合DENV的高级临床试验
黄热病病毒(YFV)疫苗仅报道了部分保护作用,并未显示出对所有DENV的疗效
血清型或在DENV幼稚受试者中。最令人担忧的是,最近的数据表明赛诺菲疫苗可能会
在幼稚的受试者中加强症状性疾病,这对其最终部署提出了问题。
缺乏已建立的疫苗诱导保护的免疫相关性,阻碍了一种
对DENV和其他几种传染病安全有效的疫苗。最近的概念和
我们对细胞和体液免疫效应机制的了解的技术进步为
实施新的检测方法以确定疫苗效力的机制和相关性的前进方向。一种新的
DENV减毒活疫苗目前正在巴西进行测试,巴西是DENV
达到了流行的程度。该TV003疫苗配方包括三个相应的减毒株
对不同的DENV血清型(DENV-1、DENV-3和DENV-4)和第四个嵌合株(DENV-2/DENV-4),
它包含DENV-2结构基因和DENV-4非结构基因。其中一个主要的
TV003疫苗相对于赛诺菲DENV-YFV疫苗的优点是其所有成分都是
来自DENV毒株。该疫苗的第二阶段试验已经完成,第三阶段试验已经启动。
将包括超过17,000个主题。第二阶段和第三阶段试验都已获得动力,以包括足够的
受试者接受培训和测试/验证队列。外周血单核细胞、血清和血浆
已经收集了这两项里程碑式研究中包括的所有主题的信息。我们研究的主要目标是
将是比较、排序和选择预测免疫原性和有效性的最佳检测方法
疫苗。我们将检验这一假设,即需要几种成分(细胞成分、体液成分和固有成分)
以触发该疫苗诱导的保护作用。将在这里测试的化验方法涵盖了广泛的
细胞和体液免疫反应的效应机制阵列以及新的全基因组
对先天免疫和获得性免疫的公正评估。一棵严谨的决策树将允许我们进入目标1
识别和验证预测疫苗引发针对所有四种疫苗的广泛免疫反应的分析
该疫苗中包括的DENV毒株。在目标2中,我们将确定同类中最好的分析方法(S),它可以预测
疫苗在保护受者免受感染方面的效力。疗效将包括病例和
控制疫苗的有效率是否低于80%;或者,我们将比较接种疫苗的人和自然感染的人
如果疫苗高效,则使用安慰剂(>;85%)。在Aim 3中,我们的企业合作伙伴Caprion
在开发临床结果预测指标方面的长期经验,将进一步优化和扩大检测方法(S)
在目标1(免疫原性)和目标2(有效性)中确定所需的稳健性、准确性和吞吐量
用于DENV疫苗试验的广泛临床应用,可能还有其他病毒。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rafick Pierre Sekaly其他文献
Rafick Pierre Sekaly的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rafick Pierre Sekaly', 18)}}的其他基金
MultiOMICS mechanistic identification of predictors of HIV DNA decay, restoration of immune homeostasis and HIV specific immunity in PWH with cancer receiving Immune check point therapy
接受免疫检查点治疗的癌症患者中 HIV DNA 衰变、免疫稳态恢复和 HIV 特异性免疫的预测因子的多组学机制鉴定
- 批准号:
10731665 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Harnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIV
在 cART 治疗的感染 SIV 的猕猴中利用 IL-10 恢复免疫力并根除 HIV
- 批准号:
10588314 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Multi-OMICS identification and validation of mechanisms triggered by Immune interventions aimed at reducing the size of the replication competent Reservoir
多组学鉴定和验证免疫干预触发的机制,旨在减少复制能力储库的大小
- 批准号:
10731661 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
I2 Control= Modulating Innate Immunity to Achieve Control of HIV
I2 Control= 调节先天免疫以实现对 HIV 的控制
- 批准号:
10731664 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Emory/Georgia TB Research Advancement Center (TRAC)
埃默里/佐治亚州结核病研究促进中心 (TRAC)
- 批准号:
10429404 - 财政年份:2022
- 资助金额:
$ 126.47万 - 项目类别:
Emory/Georgia TB Research Advancement Center (TRAC)
埃默里/佐治亚州结核病研究促进中心 (TRAC)
- 批准号:
10596182 - 财政年份:2022
- 资助金额:
$ 126.47万 - 项目类别:
A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials
采用多层方法开发经过验证的检测方法,以预测四价登革热病毒减毒活疫苗在 II 期和 III 期临床试验中的功效
- 批准号:
10341373 - 财政年份:2021
- 资助金额:
$ 126.47万 - 项目类别:
Investigating the impact of helminth infection on microbioma composition and innate immunity generated during HepB vaccination.
研究蠕虫感染对乙型肝炎疫苗接种过程中微生物群组成和先天免疫的影响。
- 批准号:
10163555 - 财政年份:2020
- 资助金额:
$ 126.47万 - 项目类别:
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
癌症和自身免疫中 COVID-19 感染的免疫调节
- 批准号:
10222321 - 财政年份:2020
- 资助金额:
$ 126.47万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 126.47万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 126.47万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 126.47万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 126.47万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 126.47万 - 项目类别:














{{item.name}}会员




